Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

DOI: https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Emilie Cayssials, Gabriel Etienne, Ali G Turhan, Philippe Rousselot, Valerie Coiteux, Marc G. Berger, Francoise Huguet, Agnes Guerci-Bresler

Blood (2022) 140 (Supplement 1): 6776–6777.

DOI: https://doi.org/10.1182/blood-2022-166111

Published: 2022

Journal Articles

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Franck E. Nicolini, Francoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Aurore Yocolly, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 9656–9658.

DOI: https://doi.org/10.1182/blood-2022-160268

Published: 2022

Journal Articles

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Blood (2022) 140 (Supplement 1): 507–509.

DOI: https://doi.org/10.1182/blood-2022-159397

Published: 2022

Journal Articles

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Pierre Luc Mouchel, Sarah Bertoli, Emilie Berard, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Laetitia Largeaud, Nathan Guiraud, Jean-Emmanuel Sarry, Audrey Sarry, Francoise Huguet, Suzanne Tavitian, Christian Recher

Blood (2022) 140 (Supplement 1): 3239–3241.

DOI: https://doi.org/10.1182/blood-2022-166373

Published: 2022

Journal Articles

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Pilar Martínez Sánchez, Gerhard Zugmaier, Paul Gordon, Elias Jabbour, José J. Rifón Roca, Stefan Schwartz, Erika Borlenghi, Francoise Huguet, Jesús María Hernández-Rivas, Federico Lussana, Céline Berthon, Priti Kadu, Hansen Wong, Ana Markovic, Yuliya Katlinskaya, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 6122–6124.

DOI: https://doi.org/10.1182/blood-2022-157117

Published: 2022

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Rathana KIM, Marc Delord, Michael Doubek, Francoise Huguet, Aurelie Cabannes-Hamy, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stephane Lepretre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Claude Gardin, Emmanuelle Clappier, Herve Dombret, Philippe Rousselot

Blood (2022) 140 (Supplement 1): 6114–6116.

DOI: https://doi.org/10.1182/blood-2022-166035

Published: 2022

Journal Articles

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Blood (2022) 140 (Supplement 1): 112–114.

DOI: https://doi.org/10.1182/blood-2022-157903

Published: 2022

Journal Articles

Concurrent CDX2 cis -deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

Blood (2022) 139 (24): 3505–3518.

DOI: https://doi.org/10.1182/blood.2021014723

Published: 2022

Includes: Supplemental data

Journal Articles

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL

Guillaume P. Andrieu, Milena Kohn, Mathieu Simonin, Charlotte L. Smith, Agata Cieslak, Marie-Émilie Dourthe, Guillaume Charbonnier, Carlos Graux, Françoise Huguet, Véronique Lhéritier, Hervé Dombret, Salvatore Spicuglia, Philippe Rousselot, Nicolas Boissel, Vahid Asnafi

Blood (2021) 138 (19): 1855–1869.

DOI: https://doi.org/10.1182/blood.2020010081

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

Blood (2021) 138 (Supplement 1): 215.

DOI: https://doi.org/10.1182/blood-2021-150705

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

DOI: https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Michael Doubek, Francoise Huguet, Cyril Salek, Aurélie Cabannes, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stéphane Leprêtre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Emmanuelle Clappier, Laure Morisset, Claude Gardin, Hervé Dombret, Philippe Rousselot

Blood (2021) 138 (Supplement 1): 511.

DOI: https://doi.org/10.1182/blood-2021-148625

Published: 2021

Journal Articles

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Blood (2021) 138 (Supplement 1): 3478.

DOI: https://doi.org/10.1182/blood-2021-150126

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

DOI: https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

Blood (2021) 138 (Supplement 1): 1232.

DOI: https://doi.org/10.1182/blood-2021-146163

Published: 2021

Journal Articles

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Laetitia Largeaud, Sarah Bertoli, Emilie Berard, Suzanne Tavitian, Muriel Picard, Stephanie Dufrechou, Naïs Prade, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Audrey Sarry, Francoise Huguet, Jean Ruiz, Veronique De Mas, Eric Delabesse, Christian Recher

Blood (2021) 138 (Supplement 1): 1294.

DOI: https://doi.org/10.1182/blood-2021-147497

Published: 2021

Journal Articles

Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Pilar Martínez Sánchez, Paul Gordon, Stefan Schwartz, Giuseppe Rossi, Francoise Huguet, Jesus Maria Hernández-Rivas, Priti Kadu, Hansen L. Wong, Ana Markovic, Yuliya Katlinskaya, Bharat Panwar, Gerhard Zugmaier

Blood (2021) 138 (Supplement 1): 2303.

DOI: https://doi.org/10.1182/blood-2021-150018

Published: 2021

Journal Articles

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study

Corentin Orvain, Marie Balsat, Emmanuelle Tavernier, Jean-Pierre Marolleau, Thomas Pabst, Patrice Chevallier, Noémie de Gunzburg, Victoria Cacheux, Françoise Huguet, Sylvain Chantepie, Denis Caillot, Yves Chalandon, Jamilé Frayfer, Caroline Bonmati, Véronique Lheritier, Norbert Ifrah, Hervé Dombret, Nicolas Boissel, Mathilde Hunault-Berger

Blood (2020) 136 (3): 328–338.

DOI: https://doi.org/10.1182/blood.2020004919

Published: 2020

Includes: Supplemental data

Journal Articles

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Blood (2019) 134 (Supplement_1): 1295.

DOI: https://doi.org/10.1182/blood-2019-124029

Published: 2019

NARROW

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Concurrent CDX2 cis -deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only